{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06153095",
            "orgStudyIdInfo": {
                "id": "MPCT-021N"
            },
            "organization": {
                "fullName": "ImmPACT Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study on IMPT-514 in Active Refractory Lupus (SLE)",
            "officialTitle": "A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Drug Level Monitoring, Drug Effects, and Effectiveness of IMPT-514 in Participants With Active, Refractory Kidney Involvement in Lupus and Lupus",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "study-on-impt-in-active-refractory-lupus-sle"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-22",
            "studyFirstSubmitQcDate": "2023-11-22",
            "studyFirstPostDateStruct": {
                "date": "2023-12-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ImmPACT Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in patients with active, refractory lupus nephritis and systemic lupus erythematosus.\n\nIMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Individual patients will remain in the active post-treatment period for approximately 1 year.\n\nParticipants will continue in long-term follow-up for 15 years from treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Lupus Erythematosus",
                "Lupus Nephritis"
            ],
            "keywords": [
                "CAR T-cell",
                "CD19/20",
                "CD19",
                "CD20",
                "Lupus Nephritis",
                "LN",
                "Systemic Lupus Erythematosus",
                "SLE",
                "Active refractory systemic lupus erythematosus",
                "Active refractory Lupus Nephritis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 1 Lupus Nephritis",
                    "type": "EXPERIMENTAL",
                    "description": "Administration of IMPT-514",
                    "interventionNames": [
                        "Biological: IMPT-514"
                    ]
                },
                {
                    "label": "Phase 2 Lupus Nephritis",
                    "type": "EXPERIMENTAL",
                    "description": "Administration of IMPT-514",
                    "interventionNames": [
                        "Biological: IMPT-514"
                    ]
                },
                {
                    "label": "Phase 2 SLE without Lupus Nephritis",
                    "type": "EXPERIMENTAL",
                    "description": "Administration of IMPT-514",
                    "interventionNames": [
                        "Biological: IMPT-514"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "IMPT-514",
                    "description": "CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide",
                    "armGroupLabels": [
                        "Phase 1 Lupus Nephritis"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "IMPT-514",
                    "description": "CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide",
                    "armGroupLabels": [
                        "Phase 2 Lupus Nephritis"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "IMPT-514",
                    "description": "CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide",
                    "armGroupLabels": [
                        "Phase 2 SLE without Lupus Nephritis"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase I: Incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), and other treatment-emergent adverse events (TEAEs).",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Phase I: Incidence of TEAEs, percent reduction in peripheral B cells, and the proportion of enrolled participants who receive the target dose.",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Phase II: Cohort 1: Proportion of participants with Complete Renal Response (CRR) as defined by EULAR/ERA-EDTA at Month 6.",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Phase II: Cohort 2: Proportion of participants achieving DORIS remission at Month 6.",
                    "timeFrame": "Baseline to Month 6"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Age 18 years of age or older\n3. Weight \\> 45 kg at enrollment\n4. Adequate blood pressure control\n5. Diagnosis of SLE by 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria or 2012 Systemic Lupus Collaborating Clinics (SLICC) criteria, including positive ANA or positive anti-dsDNA\n6. LN participants: Active, biopsy-proven, proliferative lupus nephritis Class III or IV by 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria\n\nOther protocol-defined criteria apply.\n\nExclusion criteria:\n\n1. Any clinically significant underlying illness, other than SLE and LN, which would pose a safety risk or concern, as determined by the Investigator\n2. Any other systemic autoimmune condition\n3. Rapidly progressive glomerulonephritis\n4. Active central nervous system (CNS) lupus\n5. History of allogeneic bone marrow or stem cell transplantation or solid organ transplantation\n\nOther protocol-defined criteria apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "University of California, Los Angeles (UCLA) Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lori Sahakian",
                            "role": "CONTACT",
                            "phone": "310-794-9236",
                            "email": "lsahakian@mednet.ucla.edu"
                        },
                        {
                            "name": "Maureen A McMahon",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California San Francisco",
                    "status": "NOT_YET_RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jonathan Graf",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "University of Iowa",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Darby Donovan",
                            "role": "CONTACT",
                            "phone": "319-384-9643",
                            "email": "darby-donovan@uiowa.edu"
                        },
                        {
                            "name": "Hanna Zembrzuska",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "Henry Ford Health System",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alireza Meysami",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "University of Cincinnati (UC) - Department of Nephrology",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45219",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Leksi Travitz",
                            "role": "CONTACT",
                            "email": "Leksi.Travitz@uc.edu"
                        },
                        {
                            "name": "Manish Anand",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Westmead Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Westmead",
                    "zip": "NSW 2145",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Gerard Chu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.80383,
                        "lon": 150.98768
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009393",
                    "term": "Nephritis"
                },
                {
                    "id": "D000008181",
                    "term": "Lupus Nephritis"
                },
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000005921",
                    "term": "Glomerulonephritis"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12338",
                    "name": "Nephritis",
                    "asFound": "Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11178",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9031",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                },
                {
                    "id": "T3523",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2525",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}